Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapeutics for on...
Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapeutics for onco...
SAN DIEGO, and CALGARY, AB, June 20, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-...
Innovative Multimillion-Dollar Grant Was Created in 2022 to Drive Biopharma Industry to Speed Development of Pancreatic Cancer ...
RBC Capital analyst Douglas Miehm reiterates Oncolytics Biotech (TSX:ONC) with a Outperform and maintains C$6 price target.
Oncolytics Biotech® Inc. ("Oncolytics" or the "Company") (NASDAQ:ONCY) (TSX:ONC) today announced the closing (...
Canaccord Genuity analyst John Newman reiterates Oncolytics Biotech (NASDAQ:ONCY) with a Buy and maintains $5 price target.
Cantor Fitzgerald analyst Louise Chen reiterates Oncolytics Biotech (TSX:ONC) with a Overweight and maintains C$9 price target.
Cantor Fitzgerald analyst Louise Chen reiterates Oncolytics Biotech (TSX:ONC) with a Overweight and maintains C$9 price target.
